Protein clearance is enhanced by treatment with vaccines or antibodies and both, active (Troquier et al., 2012; Ando et al., 2014) and passive immunotherapies (Courade et al., 2018; Albert et al., 2019) to target tau have yielded promising results, with several clinical trials for AD and related tauopathies now in progress (Table 1) (Sandusky-Beltran and Sigurdsson, 2020). Here, MAPT is linked to tauopathy.